ライフサイエンスコーパス: large-cell lymphoma

1 NS relapse or dissemination in patients with large cell lymphoma.

2 hronic lymphocytic leukemia (CLL) to diffuse large cell lymphoma.

3 ells of Hodgkin's lymphoma and by anaplastic large cell lymphoma.

4 hase 3 trial in recurrent/refractory diffuse large cell lymphoma.

5 ymphomatoid papulosis to systemic anaplastic large cell lymphoma.

6 e treatment of advanced cutaneous anaplastic large cell lymphoma.

7 eatment similar to that reported for diffuse large cell lymphoma.

8 iate- or high-grade lymphoma, 13 had diffuse large cell lymphoma.

9 equently translocated and mutated in diffuse large cell lymphoma.

10 bility to transform B lymphocytes in diffuse large cell lymphoma.

11 als in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.

12 ng classical Hodgkin lymphoma and anaplastic large cell lymphoma.

13 ed in a patient with alk-positive anaplastic large-cell lymphoma.

14 prominently follicular lymphoma and diffuse large-cell lymphoma.

15 ic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma.

16 6 from lymphoblastic lymphoma, and five from large-cell lymphoma.

17 otherapy compared with other types of B-cell large-cell lymphoma.

18 factors for CNS recurrence in patients with large-cell lymphoma.

19 cell lymphoma and two ferrets had high-grade large-cell lymphoma.

20 ntial Ig sequence analysis in 1 patient with large-cell lymphoma.

21 atients with Hodgkin lymphoma and anaplastic large-cell lymphoma.

22 with refractory solid tumours and anaplastic large-cell lymphoma.

23 nd blood samples of patients with anaplastic large-cell lymphoma.

24 primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma.

25 jected SCID mice developed aggressive murine large cell lymphomas.

26 istinguishing this disease from ALK-negative large cell lymphomas.

27 n of follicular lymphomas to more aggressive large cell lymphomas.

28 ng Classical Hodgkin and systemic anaplastic large cell lymphomas.

29 n gammaHV68-infected animals were B220+/CD3- large-cell lymphomas.

30 y represent the cell of origin of some human large-cell lymphomas.

31 indistinguishable from patients' anaplastic large-cell lymphomas.

32 characteristic of patient-derived anaplastic large-cell lymphomas.

33 ]), angiocentric lymphoma (4/4), a subset of large-cell lymphomas (10/21 [48%]), and lymphomas with a

34 Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not

35 ALK)-positive and 48 ALK-negative anaplastic large cell lymphoma, 14 adult T-cell leukemia/lymphoma a

36 Three patients had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sezary

37 oid granulomatosis), 12/19 T-cell anaplastic large-cell lymphomas, 2/12 nodal peripheral T-cell lymph

38 In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entities were CD

39 One patient with cutaneous anaplastic large cell lymphoma (8 mg/kg) achieved a complete respon

40 Patients who undergo transformation to large-cell lymphoma (8% to 23% of patients) have a poor

41 to 3% of patients per year into aggressive, large cell lymphoma, a critical event in the course of t

42 (8 out of 34) activated B cell-like diffuse large cell lymphoma (ABC-DLBCL), but not in GC B cell-li

43 of MALT lymphoma to activated B-cell diffuse large-cell lymphoma (ABC-DLBCL).

44 All seven patients without anaplastic large-cell lymphoma achieved CR.

45 ose expression is up-regulated on anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) cel

46 the neoplastic transformation of anaplastic large cell lymphoma (ALCL) and the Reed-Sternberg cell o

47 contributes to the oncogenesis of anaplastic large cell lymphoma (ALCL) are not completely understood

48 We used various ALK-positive anaplastic large cell lymphoma (ALCL) cell lines to evaluate two in

49 malignant lymphocytes, including anaplastic large cell lymphoma (ALCL) cells.

50 ic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) constitutes an ideal model di

51 malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually

52 ic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) frequently carries the t(2;5)

53 dies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical suc

54 ority of LyP patients progress to anaplastic large cell lymphoma (ALCL) in which skin lesions no long

55 ic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a CD30-positive T-cell non

56 Anaplastic large cell lymphoma (ALCL) is a distinct clinicopatholog

57 Anaplastic large cell lymphoma (ALCL) is a distinct entity of T-cel

58 Anaplastic large cell lymphoma (ALCL) is a highly proliferative neo

59 Anaplastic large cell lymphoma (ALCL) is a mature T-cell lymphoma t

60 Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lympho

61 Systemic anaplastic large cell lymphoma (ALCL) is an aggressive CD30(+) non-

62 Anaplastic large cell lymphoma (ALCL) is composed of large, frequen

63 Anaplastic large cell lymphoma (ALCL) is the most common type of pe

64 In the DHL cell line, an Anaplastic Large Cell Lymphoma (ALCL) line, a DNA rearrangement was

65 a subset of T-cell lymphomas with anaplastic large cell lymphoma (ALCL) morphology (ALK+ ALCL), the v

66 s detected in LyP lesions and the anaplastic large cell lymphoma (ALCL) of 2 patients and the mycosis

67 lymphoma kinase-positive (ALK(+)) anaplastic large cell lymphoma (ALCL) patients.

68 In ALK-rearranged anaplastic large cell lymphoma (ALCL), a specific subtype of T-cell

69 sed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL), the single agent response ra

70 he biology and treatment of CD30+ anaplastic large cell lymphoma (ALCL), we transplanted leukemic tum

71 LK) are detected in 50% to 70% of anaplastic large cell lymphoma (ALCL), which is a T/null cell non-H

72 in (NPM)-ALK fusion protein in an anaplastic large cell lymphoma (ALCL)-derived cell line carrying th

73 ncluding Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL).

74 expressed in a subset of cases of anaplastic large cell lymphoma (ALCL).

75 expressed in a subset of systemic anaplastic large cell lymphoma (ALCL).

76 (ALK) consistent with a null cell anaplastic large cell lymphoma (ALCL).

77 n and malignant transformation of anaplastic large cell lymphoma (ALCL).

78 cells of Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL).

79 psed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL).

80 sed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).

81 y efficacious in animal models of anaplastic large cell lymphoma (ALCL).

82 ic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).

83 netic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibrobla

84 haracteristically translocated in Anaplastic Large Cell Lymphomas (ALCL) and the juxtaposition of the

85 The subset of CD30-positive anaplastic large cell lymphomas (ALCL) with the NPM-ALK gene fusion

86 nucleophosmin-ALK oncoprotein in anaplastic large cell lymphomas (ALCL).

87 (NSCLC) and approximately 70% of anaplastic large cell lymphomas (ALCL).

88 -derived neoplasias, most notably anaplastic large-cell lymphoma (ALCL) and Hodgkin's lymphoma.

89 herapy of certain cancers such as anaplastic large-cell lymphoma (ALCL) and inflammatory myofibroblas

90 ents in several tumors, including anaplastic large-cell lymphoma (ALCL) and non-small cell lung carci

91 s) are expressed in many cases of anaplastic large-cell lymphoma (ALCL) but are absent from normal ti

92 Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(2;5; p23;q3

93 , was specifically found in all 4 anaplastic large-cell lymphoma (ALCL) cell lines, but not in any of

94 Anaplastic large-cell lymphoma (ALCL) frequently carries the t(2;5)

95 % of patients with advanced-stage anaplastic large-cell lymphoma (ALCL) harbor the balanced chromosom

96 c proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) have been well defined; never

97 Anaplastic large-cell lymphoma (ALCL) is a clinical and biological

98 Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently described clini

99 Systemic anaplastic large-cell lymphoma (ALCL) is a T-cell lymphoma, whose a

100 Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T

101 Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by some to be a

102 on-Hodgkin lymphoma (NHL) subtype anaplastic large-cell lymphoma (ALCL) is frequently associated with

103 otein (Rb) in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is unknown.

104 ficance of survivin expression in anaplastic large-cell lymphoma (ALCL) is unknown.

105 c proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is well established.

106 Anaplastic large-cell lymphoma (ALCL) of T- or null-cell lineage, a

107 Anaplastic large-cell lymphoma (ALCL) provides an excellent example

108 Anaplastic large-cell lymphoma (ALCL) represents a heterogeneous gr

109 regulated in T-lymphomas, such as anaplastic large-cell lymphoma (ALCL) tumors.

110 c lymphoma kinase (ALK) -positive anaplastic large-cell lymphoma (ALCL) was excluded.

111 Anaplastic large-cell lymphoma (ALCL) was initially recognized on t

112 lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and adult T-cell leukemia/ly

113 dgkin's lymphoma (HL), three with anaplastic large-cell lymphoma (ALCL), and two with CD30+ T-cell ly

114 5) translocation, associated with anaplastic large-cell lymphoma (ALCL), results in the production of

115 In anaplastic large-cell lymphoma (ALCL), the (2;5) chromosomal transl

116 ts with Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), the study by Jacobsen and co

117 LK) in patients with ALK-positive anaplastic large-cell lymphoma (ALCL).

118 portant pathogenetic role in ALK+ anaplastic large-cell lymphoma (ALCL).

119 contribute to oncogenesis in ALK+ anaplastic large-cell lymphoma (ALCL).

120 losely represent a model of human anaplastic large-cell lymphoma (ALCL).

121 -3 in all of the 8 cases of Ki-1+ anaplastic large-cell lymphoma (ALCL).

122 ic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL).

123 an lymphoma (initially designated anaplastic large cell lymphoma [ALCL] or Ki-1/CD30-positive lymphom

124 7 Burkitt's lymphoma [BL], and 4 anaplastic large cell lymphoma [ALCL]), and 25 nonmalignant lymph n

125 astic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL]) is difficult, with the morph

126 ts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).

127 Anaplastic large cell lymphomas (ALCLs) are caused by chromosomal t

128 The majority of pediatric anaplastic large cell lymphomas (ALCLs) carry the t(2;5)(p23;q35) c

129 Anaplastic Large Cell Lymphomas (ALCLs) carry translocations in whi

130 ion in lymphomas, with a focus on anaplastic large cell lymphomas (ALCLs), which are known to express

131 aplastic lymphoma kinase (ALK)(-) anaplastic large cell lymphomas (ALCLs).

132 ccurring in approximately half of anaplastic large cell lymphomas (ALCLs).

133 event in the pathogenesis of most anaplastic large cell lymphomas (ALCLs).

134 Anaplastic large-cell lymphomas (ALCLs) are a group of clinically a

135 cutaneous and primary nodal CD30+ anaplastic large-cell lymphomas (ALCLs) are distinct clinical entit

136 Anaplastic large-cell lymphomas (ALCLs) bearing the t(2;5) transloc

137 Anaplastic large-cell lymphomas (ALCLs) encompass at least 2 system

138 the survival and proliferation of anaplastic large-cell lymphomas (ALCLs).

139 ic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALK-negative), despite their unique

140 aplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK(+) ALCL) is a unique type of T-

141 iated with an improved outcome in anaplastic large-cell lymphoma, ALK positive.

142 contrast, the malignant cells in anaplastic large cell lymphoma and most high-grade tumors, includin

143 Virtually all diffuse large cell lymphomas and a significant fraction of folli

144 are among the most common lesions in diffuse large-cell lymphoma and have been associated with a poor

145 f the ALK tyrosine kinase gene in anaplastic large-cell lymphoma and inflammatory myofibroblastic tum

146 ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tum

147 y expressed in a subset of T-cell anaplastic large-cell lymphoma and non-small-cell lung cancer, resp

148 The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of

149 /flow-positive cases were from patients with large-cell lymphomas and bulky clinical disease.

150 gh levels of BSAP, especially those found in large-cell lymphomas and in some follicular lymphomas, m

151 activated B-like from germinal-center B-like large-cell lymphomas and provide important pathobiologic

152 pression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine I

153 's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progressio

154 (14 large-B-cell lymphomas and 10 anaplastic large-cell lymphomas), and 15 highly aggressive lymphoma

155 angioimmunoblastic, ALK-negative anaplastic large cell lymphoma, and enteropathy-associated T-cell l

156 , respectively, for patients with anaplastic large-cell lymphoma, and 63.8% (SE, 10.3%) and 70.3% (SE

157 t otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma, and adult T-cell leukemia/lymphoma

158 e-cell immunoblastic lymphoma and anaplastic large-cell lymphoma, and all 12 cases studied lacked c-m

159 is (LyP), anaplastic and nonanaplastic CD30+ large-cell lymphoma, and borderline cases, comprise a cl

160 nsplantation in patients with diffuse B-cell large-cell lymphoma, and, specifically, to evaluate the

161 fuse large cell B-cell lymphomas, anaplastic large-cell lymphomas, and Epstein-Barr virus-induced B-c

162 amine T-cell lymphomas, including anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma,

163 Rare histologies include Ki-1 anaplastic large cell lymphoma, angiotropic large cell lymphoma, mu

164 Approximately 40% of diffuse large cell lymphoma are associated with chromosomal tran

165 phoma kinase (NPM-ALK) expressing anaplastic large cell lymphoma are not completely understood.

166 Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expre

167 mphomas of T or NK phenotype, and anaplastic large-cell lymphomas are cytotoxic T-or NK-cell neoplasm

168 and develop the morphologic appearance of a large cell lymphoma, are undefined.

169 B cell diffuse large cell lymphoma (B-DLCL) is a heterogeneous group of

170 ure-free survival (FFS) for PTCLs and B-cell large-cell lymphomas (BCLCLs) is 38% and 55%, respective

171 Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare peripheral T-cell

172 of relapsed Hodgkin and systemic anaplastic large cell lymphomas--both characterized by high express

173 breaks and translocations in the anaplastic large cell lymphoma breakpoint regions of NPM1 and ALK.

174 of relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma by the Food and Drug Administration.

175 ree of 10 primary cutaneous CD30+ anaplastic large-cell lymphoma (C-ALCL).

176 of the Hodgkin's disease cases, eight of the large-cell lymphoma cases, and six of the lymphomatoid p

177 In anaplastic large cell lymphoma, CD30 triggering induces growth arre

178 to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lympho

179 ase (ALK)-positive and -negative, anaplastic large cell lymphoma cell lines and primary patient tumou

180 plastic lymphoma kinase-positive, anaplastic large cell lymphoma cell lines and that ectopically expr

181 NPM/ALK-negative, patient-derived anaplastic large cell lymphoma cell lines.

182 rge B-cell lymphoma, ALK-positive anaplastic large cell lymphoma, chronic myelogenous leukemia, and a

183 morphologically more high grade (50% diffuse large cell lymphoma) compared with primary CL (37% low-g

184 In patients with diffuse large-cell lymphoma (DLBCL), we observed higher levels o

185 -cell lymphomas (DMxs), and 16 of 84 diffuse large-cell lymphomas (DLCCs); the difference between the

186 disease case (MAL) and KI-1 positive diffuse large cell lymphoma (DLCL) cell line (KIS-1).

187 of aberrant somatic hypermutation in diffuse large cell lymphoma (DLCL), the most common form of non-

188 data set based on 160 patients with diffuse large cell lymphoma (DLCL).

189 0.57; 0.34-0.94), particularly with diffuse large cell lymphoma (DLCL; OR = 0.29; 0.10-0.82).

190 In approximately 40% of diffuse large cell lymphomas (DLCL) and approximately 14% of fol

191 NHL and of two predominant subtypes, diffuse large-cell lymphoma (DLCL) (n = 233) and follicular lymp

192 eatures of 71 cases of primary CD30+ diffuse large-cell lymphomas (DLCL) and 128 cases of Hodgkin's d

193 ious other partners are recurrent in diffuse large-cell lymphomas (DLCL).

194 CPP32 was present in 10 of 12 (83%) diffuse large cell lymphomas (DLCLs) and 2 of 3 diffuse mixed B-

195 (ARHH) and PAX5, in more than 50% of diffuse large-cell lymphomas (DLCLs), which are tumours derived

196 showed morphologic transformation to diffuse large-cell lymphoma (DLL) in the second biopsy.

197 as (DSCCs), 2 of 17 diffuse mixed small- and large-cell lymphomas (DMxs), and 16 of 84 diffuse large-

198 2;5) translocation in a subset of anaplastic large cell lymphomas, encodes a Mr 75,000 hybrid protein

199 ed by the t(2;5) translocation in anaplastic large-cell lymphoma, encodes a M(r) 75,000 hybrid protei

200 l T-cell lymphomas--including one anaplastic large cell lymphoma--expressed CD95.

201 stologic classification revealed 21 cases of large cell lymphoma, five cases of lymphoblastic lymphom

202 It is debated whether follicular large cell lymphoma (FLCL) has a clinical behavior that

203 follicular mixed cells (FMs) and follicular large cell lymphomas (FLCLs) was strongly CPP32 immunopo

204 rge-cell lymphomas (FMxs), 1 of 4 follicular large-cell lymphomas (FLCs), 1 of 14 diffuse small cleav

205 f 35 follicular mixed small cleaved-cell and large-cell lymphomas (FMxs), 1 of 4 follicular large-cel

206 mechanism for escape of cutaneous anaplastic large cell lymphoma from tumor regression.

207 and ATLL and a lower incidence of anaplastic large-cell lymphoma; Hispanics had a higher incidence of

208 patients, particularly those with anaplastic large-cell lymphoma histology.

209 e molecular features of EBV-positive diffuse large cell lymphomas in 2 patients with RA.

210 t's lymphoma and Epstein-Barr-virus-negative large-cell lymphoma in AIDS patients, but not in immunos

211 , or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumour

212 e disorders, and that lymph node-based CD30+ large cell lymphoma is a disease that is biologically di

213 Breast implant-associated anaplastic large cell lymphoma is a rare cancer in patients with br

214 Anaplastic large-cell lymphoma is associated with a chromosomal tra

215 In T-cell lymphomas, anaplastic large-cell lymphoma is defined by mutually exclusive rea

216 pressed on Hodgkin's lymphoma and anaplastic large cell lymphoma, it is a promising target for immuno

217 interfering RNA transfection of T-anaplastic large cell lymphoma Karpas 299.

218 More than 60% of anaplastic large-cell lymphomas (Ki-1 lymphoma) are associated with

219 transcriptase-polymerase chain reaction), 1 large cell lymphoma (LCL) arising subsequent to MALT lym

220 ymphoma (NHL) subset commonly referred to as large cell lymphoma (LCL) has historically been characte

221 Large-cell lymphoma (LCL) arising in the mediastinum (LC

222 ients with small non-cleaved-cell (SNCL) and large-cell lymphoma (LCL) treated with intensive chemoth

223 ligible pediatric patients with stage III/IV large-cell lymphoma (LCL); 90 patients were randomly ass

224 the relationship to composite or sequential large-cell lymphomas (LCLs) is poorly understood.

225 target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cy

226 RB is involved in differentiation, the U937 large-cell lymphoma line was induced to differentiate al

227 geneous histologic type of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small n

228 anaplastic large cell lymphoma, angiotropic large cell lymphoma, mucosa-associated lymphoid tissue,

229 as robust enough to differentiate anaplastic large cell lymphoma (n = 32) from other PTCLs.

230 a in patients with secondary CL were diffuse large cell lymphoma (n = 5, 28%), chronic lymphocytic le

231 T-cell lymphoma/leukemia (n = 4), anaplastic large-cell lymphoma (n = 2), and extranodal natural kill

232 Hodgkin's disease (twelve cases), and CD30+ large-cell lymphoma (nine cases) was tested for the HTLV

233 ubset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and n

234 ympho-hematopoietic malignancies, anaplastic large cell lymphoma (NPM-ALK) and acute promyelocytic le

235 d with oral methotrexate (MTX) who developed large cell lymphoma of B cell phenotype.

236 apulosis, seven with primary cutaneous CD30+ large cell lymphoma of T-cell lineage, and five with Hod

237 apulosis (14 cases), primary cutaneous CD30+ large cell lymphoma of T-lineage (10 cases) and Hodgkin'

238 a high proportion of lymph node-based CD30+ large cell lymphomas of T-cell lineage.

239 ymphomas (37 of 40 cases) as well as diffuse large-cell lymphomas of B-cell type (35 cases) did not e

240 lymphoma and treated patients with advanced large-cell lymphoma on a separate protocol (doxorubicin,

241 K aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three

242 In SCID mouse xenograft models of anaplastic large cell lymphoma or Hodgkin disease, cAC10-vcMMAE was

243 mphoma (P =.0005) and an increase in diffuse large cell lymphoma (P <.0001).

244 ation detected in the majority of anaplastic large cell lymphoma patients, and has recently been impl

245 16 relapsed CLL and 9 RT (all proven diffuse large cell lymphoma) patients were enrolled, and 60% rec

246 om 31 (34%) had a primary mediastinal B-cell large-cell lymphoma (PML).

247 valuable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom

248 actory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, relapsed or refractory B-cell precu

249 rhabdomyosarcoma, neuroblastoma, anaplastic large cell lymphoma, renal cell carcinoma, and inflammat

250 In patients with diffuse large-cell lymphoma, serum interleukin-6 levels are an i

251 NPM-ALK expression in mice causes B-lineage large-cell lymphoma, suggesting a direct causative role

252 For 21 patients with relapsed or refractory large cell lymphoma, the EFS rate was 81% and the OS rat

253 ymphoma and, in a subset of cases of diffuse large cell lymphoma, the mechanism of Bcl-6 overexpressi

254 vided clues toward the outcome of anaplastic large cell lymphoma; the breakpoints of t(2;5) were mapp

255 cases of the non-Hodgkin's lymphoma, diffuse large cell lymphoma, there are translocations of the BCL

256 aplastic lymphoma kinase-positive anaplastic large cell lymphoma), upfront auto-SCT was associated wi

257 We examined a series of marine RAW117 large cell lymphoma variants selected in vivo for liver-

258 oid papulosis and cutaneous CD30+ anaplastic large cell lymphoma was shown, suggesting that activatio

259 s fungoides (T-MF), and cutaneous anaplastic large cell lymphoma were studied in parallel with corres

260 licular small cleaved and five of 13 diffuse large cell lymphomas were KAI1 negative.

261 2-like PTCL studied, all cases of anaplastic large cell lymphoma, were immunoreactive for LEF-1 or TC

262 is fungoides or primary cutaneous anaplastic large-cell lymphoma who had been previously treated.

263 118 untreated patients with diffuse large-cell lymphoma who were enrolled in frontline chemo

264 ease often transforms into a more aggressive large cell lymphoma with a rapidly progressive clinical

265 w-negative cases included 5 follicular and 5 large-cell lymphomas with minimal marrow involvement.

266 -ALK) is a key oncogenic event in anaplastic large-cell lymphomas with the characteristic chromosomal

267 ry syndrome, or primary cutaneous anaplastic large cell lymphoma, with disease progression after >/=

268 hematologic malignancies such as anaplastic large cell lymphoma, yet these mAb have not been efficac